Delaware biotech iBio pursuing Fabry disease biosimilar ERT
This article was originally published in Scrip
Executive Summary
After acquiring certain rights from Kentucky Bioprocessing for an undisclosed amount, Newark, Delaware-based iBio has started a programme to develop a biosimilar version of an enzyme to treat Fabry disease, a rare, inherited progressive disease caused by a deficiency of the alpha galactosidase A (α-Gal A) enzyme, whose function is to break down a fatty substance known as globotriaosylceramide.